Mortality among patients with familial hypercholesterolemia: A registry-based study in norway, 1992-2010

Journal of the American Heart Association

Volumn 3, Issue 6, 2014, Pages

  Mundal, Liv ^a   Sarancic, Mirza ^a   Ose, Leiv ^a   Iversen, Per Ole ^a,b   Borgan, Jens Kristian ^c   Veierød, Marit B ^a,b   Leren, Trond P ^d   Retterstøl, Kjetil ^a,b  

^a OSLO UNIVERSITY HOSPITAL   (Norway)

^b UNIVERSITY OF OSLO   (Norway)

^c STATISTICS NORWAY   (Norway)

^d ULLEVÅL UNIVERSITY HOSPITAL   (Norway)

Author keywords

Cardiovascular diseases; Hypercholesterolemia; Mortality; Registries; Statins

Indexed keywords

ANTILIPEMIC AGENT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LDLR PROTEIN, HUMAN; LOW DENSITY LIPOPROTEIN RECEPTOR;

ADOLESCENT; ADULT; AGE DISTRIBUTION; AGED; APHERESIS; ARTICLE; CANCER MORTALITY; CARDIOVASCULAR DISEASE; CARDIOVASCULAR MORTALITY; CAUSE OF DEATH; CHILD; COHORT ANALYSIS; CONTROLLED STUDY; FAMILIAL HYPERCHOLESTEROLEMIA; FEMALE; HUMAN; INFANT; MAJOR CLINICAL STUDY; MALE; MORTALITY; NEOPLASM; NORWAY; NORWEGIAN (PEOPLE); PRIORITY JOURNAL; STANDARDIZED MORTALITY RATIO; CARDIOVASCULAR DISEASES; EPIDEMIOLOGY; GENETIC PREDISPOSITION; GENETICS; HETEROZYGOTE; HYPERLIPOPROTEINEMIA TYPE II; MIDDLE AGED; MUTATION; PEDIGREE; PHENOTYPE; REGISTER; RISK ASSESSMENT; RISK FACTOR; TIME; TREATMENT OUTCOME; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CARDIOVASCULAR DISEASES; CAUSE OF DEATH; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HETEROZYGOTE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERLIPOPROTEINEMIA TYPE II; MALE; MIDDLE AGED; MUTATION; NORWAY; PEDIGREE; PHENOTYPE; RECEPTORS, LDL; REGISTRIES; RISK ASSESSMENT; RISK FACTORS; TIME FACTORS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84931028781     PISSN: None     EISSN: 20479980     Source Type: Journal    
DOI: 10.1161/JAHA.114.001236     Document Type: Article

References (28)

1. Toleikyte I, Retterstol K, Leren TP, Iversen PO. Pregnancy outcomes in familial hypercholesterolemia: a registry-based study. Circulation. 2011;124:1606-1614.
2. Goldstein JL, Brown MS. Familial hypercholesterolemia: pathogenesis of a receptor disease. Johns Hopkins Med J. 1978;143:8-16.
3. Neil A, Cooper J, Betteridge J, Capps N, McDowell I, Durrington P, Seed M, Humphries SE. Reductions in all-cause, cancer, and coronary mortality in statin-treated patients with heterozygous familial hypercholesterolaemia: a prospective registry study. Eur Heart J. 2008;29:2625-2633.
4. Leren TP, Finborud TH, Manshaus TE, Ose L, Berge KE. Diagnosis of familial hypercholesterolemia in general practice using clinical diagnostic criteria or genetic testing as part of cascade genetic screening. Community Genet. 2008;11:26-35.
5. Civeira F. Guidelines for the diagnosis and management of heterozygous familial hypercholesterolemia. Atherosclerosis. 2004;173:55-68.
6. Heiberg A, Berg K. The inheritance of hyperlipoproteinaemia with xanthomatosis. A study of 132 kindreds. Clin Genet. 1976;9:203-233.
7. Nordestgaard BG, Chapman MJ, Humphries SE, Ginsberg HN, Masana L, Descamps OS, Wiklund O, Hegele RA, Raal FJ, Defesche JC, Wiegman A, Santos RD, Watts GF, Parhofer KG, Hovingh GK, Kovanen PT, Boileau C, Averna M, Boren J, Bruckert E, Catapano AL, Kuivenhoven JA, Pajukanta P, Ray K, Stalenhoef AF, Stroes E, Taskinen MR, Tybjaerg-Hansen A. Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: Consensus Statement of the European Atherosclerosis Society. Eur Heart J. 2013;34: 3478-3490a.
8. World Health Organization. Familiar Hypercholesterolaemia (FH). Geneva: Report of a second WHO Consultation; 1999.
9. Goldstein JL, Brown MS. The LDL receptor. Arterioscler Thromb Vasc Biol. 2009;29:431-438.
10. Sijbrands EJ, Westendorp RG, Defesche JC, de Meier PH, Smelt AH, Kastelein JJ. Mortality over two centuries in large pedigree with familial hypercholesterolaemia: family tree mortality study. BMJ. 2001;322:1019-1023.
11. Group SSCobot SBR. Mortality in treated heterozygous familial hypercholesterolaemia: implications for clinical management. Atherosclerosis. 1999;142: 105-112.
12. Gjertsen F. The Norwegian causes of death registry-an important data source for medical research. Tidsskr Nor Laegeforen. 2002;122:2551-2554.
13. International Statistical Classification of Diseases and Related Health Problems 10th revision, ICD-10. Available from: http://www.who.int/classifications/icd/icdonlineversions/en/. Accessed September 20, 2012.
14. Alfsen GC, Lyckander LG. Does quality control of death certificates in hospitals have an impact on cause of death statistics? Tidsskr Nor Laegeforen. 2013;133:750-755.
15. Gulsvik AK, Gulsvik A, Svendsen E, Maehle BO, Thelle DS, Wyller TB. Diagnostic validity of fatal cerebral strokes and coronary deaths in mortality statistics: An autopsy study. Eur J Epidemiol. 2011;26:221-228.
16. Laursen L, Pettersen JK, Andersen O. Dødelighed og erhverv. København: Danmarks Statistik; 2001.
17. Kirkwood BR, Sterne JAC. Essential Medical Statistics. Malden: Blackwell; 2003:268-270.
18. Borgan J-K. Yrke og dødelighet 1960-2000. Rapporter 2009/5, Statistics Norway. Available at: http://www.ssb.no/a/publikasjoner/pdf/rapp_200905.pdf. Accessed December 10, 2013.
19. Statistisk Sentralbyrá. Flest menn dør av iskemisk hjertesykdom. Rapport 2011. Available at: http://www.ssb.no/helse/statistikker/dodsarsak/aar/2011-10-14. Accessed February 26, 2012.
20. Bonovas S, Filioussi K, Sitaras NM. Statin use and the risk of prostate cancer: A metaanalysis of 6 randomized clinical trials and 13 observational studies. Int J Cancer. 2008;123:899-904.
21. Boudreau DM, Yu O, Johnson J. Statin use and cancer risk: a comprehensive review. Expert Opin Drug Saf. 2010;9:603-621.
22. Cauley JA, McTiernan A, Rodabough RJ, LaCroix A, Bauer DC, Margolis KL, Paskett ED, Vitolins MZ, Furberg CD, Chlebowski RT. Statin use and breast cancer: prospective results from the women's health initiative. J Natl Cancer Inst. 2006;98:700-707.
23. Hippisley-Cox J, Coupland C. Unintended effects of statins in men and women in England and Wales: population based cohort study using the QResearch database. BMJ. 2010;340:c2197.
24. Reiner Z, Catapano AL, De Backer G, Graham I, Taskinen MR, Wiklund O, Agewall S, Alegria E, Chapman MJ, Durrington P, Erdine S, Halcox J, Hobbs R, Kjekshus J, Filardi PP, Riccardi G, Storey RF, Wood D, Bax J, Vahanian A, Auricchio A, Baumgartner H, Ceconi C, Dean V, Deaton C, Fagard R, Filippatos G, Funck-Brentano C, Hasdai D, Hoes A, Kearney P, Knuuti J, Kolh P, McDonagh T, Moulin C, Poldermans D, Popescu BA, Sechtem U, Sirnes PA, Tendera M, Torbicki A, Vardas P, Widimsky P, Windecker S, Berkenboom G, De Graaf J, Descamps O, Gotcheva N, Griffith K, Guida GF, Gulec S, Henkin Y, Huber K, Kesaniemi YA, Lekakis J, Manolis AJ, Marques-Vidal P, Masana L, McMurray J, Mendes M, Pagava Z, Pedersen T, Prescott E, Rato Q, Rosano G, Sans S, Stalenhoef A, Tokgozoglu L, Viigimaa M, Wittekoek ME, Zamorano JL. ESC/EAS guidelines for the management of dyslipidaemias: The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Eur Heart J. 2011;32:1769-1818.
25. World Health Organization. Adherence to Long-Term Therapies: Evidence for Action, 2003. Available at: http://www.who.int/chp/knowledge/publications/adherence:report/en/. Accessed March 1, 2012.
26. Leren TP, Berge KE. Subjects with molecularly defined familial hypercholesterolemia or familial defective apoB-100 are not being adequately treated. PLoS One. 2011;6:e16721.
27. Benn M, Watts GF, Tybjaerg-Hansen A, Nordestgaard BG. Familial hypercholesterolemia in the Danish general population: prevalence, coronary artery disease, and cholesterol-lowering medication. J Clin Endocrinol Metab. 2012;97:3956-3964.
28. Miettinen OS, Cook EF. Confounding: essence and detection. Am J Epidemiol. 1981;114:593-603.